Skip to main content

Table 1 Baseline characteristics of the patient cohort (n = 379) including metastasis proportion

From: A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer

Variable Number of patientsa % total Number with metastasis % metastasis
Sex
 Female 139 36.7% 29 20.9%
 Male 240 63.3% 52 21.7%
Age
 ≤60 157 41.4% 41 26.1%
 60–70 154 40.6% 29 18.8%
 > 70 68 17.9% 11 16.2%
Familial risk
 Low 196 51.7% 34 17.3%
 Intermediate/High 183 48.3% 47 25.7%
5-FU based treatment
 5-FU treated 214 56.5% 59 27.6%
 Other/No chemo 159 42.0% 17 10.7%
 Unknown 6 1.6% 5 83.3%
Stage
 I 81 21.4% 8 9.9%
 II 158 41.7% 30 19.0%
 III 140 36.9% 43 30.7%
Location
 Colon 233 61.5% 41 17.6%
 Rectum 146 38.5% 40 27.4%
Histology
 Non-mucinous 343 90.5% 75 21.9%
 Mucinous 36 9.5% 6 16.7%
Vascular invasion
 Absence 242 63.9% 45 18.6%
 Presence 111 29.3% 30 27.0%
 Unknown 26 6.9% 6 23.1%
Lymphatic invasion
 Absence 237 62.5% 44 18.6%
 Presence 116 30.6% 31 26.7%
 Unknown 26 6.9% 6 23.1%
BRAF V600E mutation
 Absence 333 87.9% 72 21.6%
 Presence 19 5.0% 8 42.1%
 Unknown 27 7.1% 1 3.7%
  1. a Patients with MSI-H tumors and Stage IV patients were excluded. 5-FU: 5-fluorouracil